The FDA Often Doesn’t Test the Quality of Generic Drugs, So We Did - propublica.org
ProPublica investigation reveals the FDA often does not test the quality of generic drugs, raising concerns about oversight and potential risks for manufacturers.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 9, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Generic drug manufacturers (ANDA holders), API and contract manufacturers, and other pharmaceutical companies relying on FDA quality assurance. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the source.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
A ProPublica investigation reports that the FDA often does not test the quality of generic drugs, indicating potential gaps in regulatory oversight.
Who it affects
Generic drug manufacturers (ANDA holders), API and contract manufacturers, and other pharmaceutical companies relying on FDA quality assurance.
What you must do
Review internal quality assurance processes and ensure compliance with cGMP to mitigate risks from potential increased scrutiny or regulatory changes.
Deadline
Not specified in the source.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- FDA moves to expose hidden foreign drug factories, strengthen domestic production in sweeping rule proposal - foxbusiness.com
- The FDA let substandard factories ship these medications to the U.S. - michiganadvance.com
- Tom’s of Maine says it will remedy mold, bacteria problems found by FDA at Sanford plant - mainebiz.biz
- The FTC Challenges Companies’ Allegedly Improper Orange Book Patent Listings - skadden.com
- Alabama Board of Medical Examiners Issues Warning of Non-FDA-Approved Peptides - drugtopics.com